Condition
Cancer of the Brain
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 4 (1)
Trial Status
Completed2
Terminated2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02193347Phase 1Completed
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
NCT02334722Phase 4Completed
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
NCT02692898Terminated
Biomarker Analysis of Central Nervous System Tumors
NCT01100658Not ApplicableTerminated
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
Showing all 4 trials